Kenvue Inc. (NYSE:KVUE) Shares Purchased by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its holdings in Kenvue Inc. by 2.5%, now owning approximately 25.6 million shares worth about $613.88 million.
• Recent investment movements include Goldman Sachs increasing its position by 34.2%, and Vanguard Group growing its stake by 4.9%.
• Kenvue announced a quarterly dividend increase to $0.2075, with a dividend yield of 3.8% as of the forthcoming payment date on August 27th.

Charles Schwab Investment Management Inc. grew its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 2.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,606,238 shares of the company's stock after buying an additional 633,461 shares during the period. Charles Schwab Investment Management Inc. owned 1.33% of Kenvue worth $613,882,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after purchasing an additional 4,034 shares during the period. IFP Advisors Inc raised its stake in Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company's stock worth $369,000 after acquiring an additional 3,081 shares in the last quarter. Starboard Value LP acquired a new stake in shares of Kenvue in the 4th quarter valued at about $467,864,000. Kingswood Wealth Advisors LLC purchased a new stake in Kenvue in the 1st quarter valued at $413,000. Finally, Cooper Investors PTY Ltd. grew its holdings in shares of Kenvue by 39.7% during the first quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company's stock worth $20,577,000 after buying an additional 244,043 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

KVUE has been the topic of several recent analyst reports. Citigroup cut their price objective on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a report on Tuesday, July 15th. Bank of America lowered their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, July 15th. Barclays cut their price target on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Tuesday, July 15th. JPMorgan Chase & Co. dropped their target price on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, July 25th. Finally, Canaccord Genuity Group lowered their target price on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $24.38.

Kenvue Stock Performance

Shares of NYSE:KVUE traded down $0.39 during trading on Friday, hitting $21.37. The stock had a trading volume of 25,925,024 shares, compared to its average volume of 21,613,902. The stock has a 50-day simple moving average of $21.62 and a two-hundred day simple moving average of $22.41. The stock has a market capitalization of $41.00 billion, a price-to-earnings ratio of 28.88, a price-to-earnings-growth ratio of 3.58 and a beta of 0.83. Kenvue Inc. has a 12-month low of $19.75 and a 12-month high of $25.17. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.36%. The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter last year, the firm earned $0.32 EPS. The business's revenue was down 4.0% compared to the same quarter last year. On average, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th will be given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date is Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's payout ratio is 110.81%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.